Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
Clinical trial NCT03933319 · UNKNOWN
Trial details
- NCT number
- NCT03933319
- Sponsor
- Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-11
- Primary completion
- 2021-03-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.